Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.61
Shares Outstanding177.6M
Average Volume (10 days)1.4M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.71)
Sales (TTM)$6.14
Book Value (MRQ)$16.25
Cash Flow (TTM)($0.13)
Cash (MRQ)$7.71

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy16
 
Buy2
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Jean-Jacques Bienaime
Director, Chief Executive Officer
(1,500)
Sell
Oct 3, 2018
Jeff Ajer
EVP, Chief Commercial Officer
(1,000)
Sell
Oct 3, 2018
V. Bryan Lawlis
(2,150)
Sell
Sep 27, 2018
G. Eric Davis
EVP, General Counsel
(1,400)
Sell
Sep 14, 2018
G. Eric Davis
EVP, General Counsel
(200)
Sell
Sep 14, 2018

Recent SEC Filings

Insider Buy/Sell
Oct 5, 2018
Insider Buy/Sell
Oct 5, 2018
Insider Buy/Sell
Sep 28, 2018
Insider Buy/Sell
Sep 27, 2018
Company Events
Sep 24, 2018

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information